Detalhe da pesquisa
1.
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Acta Derm Venereol
; 102: adv00712, 2022 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35356990
2.
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study.
Acta Derm Venereol
; 100(19): adv00340, 2020 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33196101
3.
Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study.
Acta Derm Venereol
; 98(7): 648-654, 2018 Jul 11.
Artigo
Inglês
| MEDLINE | ID: mdl-29405245
4.
Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry.
J Dermatolog Treat
; 35(1): 2304025, 2024 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38263716
5.
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial.
J Dermatolog Treat
; 33(5): 2680-2684, 2022 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-35193441
6.
A Case of Hypercalcemia in an Immunocompetent Patient with Disseminated Mycobacterium marinum Infection with a Rain Barrel as the Most Likely Primary Source.
Eur J Case Rep Intern Med
; 8(11): 002864, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34912737
7.
Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
JAMA Dermatol
; 156(4): 393-400, 2020 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32049319
8.
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Am J Clin Dermatol
; 2024 May 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38802618